Literature DB >> 35502593

Proteasome inhibition: the dawn of novel therapies in multiple myeloma.

Monika Engelhardt1, Johannes Moritz Waldschmidt2, Ralph Wäsch2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35502593      PMCID： PMC9052908          DOI： 10.3324/haematol.2022.280857

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  3 in total

1.  The ubiquitin proteasome pathway from bench to bedside.

Authors:  Robert Z Orlowski
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2005

2.  Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.

Authors:  Paul G Richardson; Pieter Sonneveld; Michael W Schuster; David Irwin; Edward A Stadtmauer; Thierry Facon; Jean-Luc Harousseau; Dina Ben-Yehuda; Sagar Lonial; Hartmut Goldschmidt; Donna Reece; Jesus F San-Miguel; Joan Bladé; Mario Boccadoro; Jamie Cavenagh; William S Dalton; Anthony L Boral; Dixie L Esseltine; Jane B Porter; David Schenkein; Kenneth C Anderson
Journal:  N Engl J Med       Date:  2005-06-16       Impact factor: 91.245

3.  Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy.

Authors:  Jens G Lohr; Petar Stojanov; Scott L Carter; Peter Cruz-Gordillo; Michael S Lawrence; Daniel Auclair; Carrie Sougnez; Birgit Knoechel; Joshua Gould; Gordon Saksena; Kristian Cibulskis; Aaron McKenna; Michael A Chapman; Ravid Straussman; Joan Levy; Louise M Perkins; Jonathan J Keats; Steven E Schumacher; Mara Rosenberg; Gad Getz; Todd R Golub
Journal:  Cancer Cell       Date:  2014-01-13       Impact factor: 31.743
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.